Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIO3: Durvalumab + Chemotherapy for Operable Stage IIIA/B NSCLC
NCT04062708Phase 2Active, not recruiting
- Sponsor
- Alliance Foundation Trials
- Start
- Mar 2021
- Primary completion
- Feb 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Alliance Foundation Trials. Primary endpoint: N2 Nodal Clearance. Started Mar 2021; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04062708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04062708.